First Time Loading...

Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 7.33 USD 2.81%
Updated: May 2, 2024

Fulcrum Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fulcrum Therapeutics Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Fulcrum Therapeutics Inc
NASDAQ:FULC
Revenue
$2.8m
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$81.8B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%

See Also

What is Fulcrum Therapeutics Inc's Revenue?
Revenue
2.8m USD

Based on the financial report for Dec 31, 2023, Fulcrum Therapeutics Inc's Revenue amounts to 2.8m USD.

What is Fulcrum Therapeutics Inc's Revenue growth rate?
Revenue CAGR 3Y
-32%

Over the last year, the Revenue growth was -56%. The average annual Revenue growth rates for Fulcrum Therapeutics Inc have been -32% over the past three years .